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Abstract 
Background: Activation of the MET oncogene promotes tumor growth, invasion and metastasis in several tumor 
types. Additionally, MET is activated as a compensatory pathway in the presence of EGFR blockade, thus resulting in a 
mechanism of resistance to EGFR inhibitors.
Methods: We have investigated the impact of HGF and MET expression, MET activation (phosphorylation), MET gene 
status, and MET‑activating mutations on cetuximab sensitivity in recurrent or metastatic squamous cell carcinoma of 
the head and neck (HNSCC) patients.
Results: A single‑institution retrospective analysis was performed in 57 patients. MET overexpression was detected in 
58 % patients, MET amplification in 39 % and MET activation (p‑MET) in 30 %. Amplification was associated with MET 
overexpression. Log‑rank testing showed significantly worse outcomes in recurrent/metastatic, MET overexpressing 
patients for progression‑free survival and overall survival. Activation of MET was correlated with worse PFS and OS. In 
multivariate logistic regression analysis, p‑MET was an independent prognostic factor for PFS. HGF overexpression was 
observed in 58 % patients and was associated with MET phosphorylation, suggesting a paracrine activation of the 
receptor.
Conclusions: HGF/MET pathway activation correlated with worse outcome in recurrent/metastatic HNSCC patients. 
When treated with a cetuximab‑based regimen, these patients correlated with worse outcome. This supports a dual 
blocking strategy of HGF/MET and EGFR pathways for the treatment of patients with recurrent/metastatic HNSCC.
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Background
The incidence of head and neck cancer is increasing 
worldwide, and has recently become the sixth most com-
mon malignancy [1]. Malignancies of the head and neck 
are associated with tobacco use, alcohol consumption, 
and Epstein–Barr virus (EBV) and/or papillomavirus 
(HPV) infections [2]. Advances in diagnosis, prevention, 
and management of advanced cases have been made in 
recent years, and while long-term survival rates have 
improved [1], they remain some of the lowest among 
major cancer types worldwide. Head and neck squa-
mous cell carcinoma (HNSCC) is a particularly preva-
lent type of head and neck cancer, constituting 90  % of 
all head and neck cancers. Survival rates are low due to 
late diagnosis at advanced stages, the failure of treatment 
[3], and the development of secondary malignant tumors. 
These problems underscore the importance of improving 
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strategies of primary chemotherapy and chemopreven-
tion of HNSCC.
Traditionally, the concurrent use of surgery, radiation, 
and/or multiagent chemotherapy for the management of 
patients with late-stage, locoregionally advanced unre-
sectable disease has been the standard for treatment of 
HNSCC [4]. Alternatively, focus has shifted in recent 
years towards biological therapies [5]. These include 
drugs that target growth factors and their receptors, 
signal transduction, cell cycle control, protein degrada-
tion, hypoxia, and angiogenesis. Epidermal growth fac-
tor receptor (EGFR) is a receptor tyrosine-kinase that is 
overexpressed in 90 % of HNSCC tumors and is involved 
in tumor growth, invasion, metastasis, and angiogenesis 
[6]. It is an early marker of carcinogenesis in HNSCC, 
and has been associated with a poor outcome [7]. This 
makes it a reasonable target for specific biological drugs 
[8], from antibodies to small-molecule inhibitors. Cetuxi-
mab is a chimeric IgG1 monoclonal antibody that inhib-
its ligand binding to the EGFR extracellular domain [9] 
(hence interfering with receptor activation) and enhances 
the activity of chemotherapeutic agents [10]. Numerous 
clinical trials with cetuximab have improved the treat-
ment of recurrent/metastatic HNSCC both as first-line 
therapy and following failure of platinum-based chemo-
therapy [11, 12]. Since its approval for HNSCC in 2006, 
the clinical data produced suggest that cetuximab plays 
an important role in the locoregional treatment of these 
pathologies [13]. A second anti-EGFR strategy targets the 
intracellular domain of the receptor with low-molecular-
weight tyrosine kinase inhibitors (erlotinib, gefitinib) and 
influences downstream signaling processes [14]. Erlotinib 
has FDA/EMEA approval for locally advanced or meta-
static NSCLC as well as advanced or metastatic pancre-
atic carcinoma, and has also been studied in HNSCC. 
The response rate to EGFR-targeted therapies is smaller 
than expected, due to primary resistance [15] and to the 
development of acquired resistance [16]. In recurrent/
metastatic HNSCC, monoclonal antibody therapies in 
clinical trials have demonstrated superior increases in OS 
and PFS than tyrosine kinase inhibitors [17, 18]. There-
fore, it is important to gain knowledge of the molecular 
mechanisms of drug resistance since the identification of 
the tumors that rely on EGFR signaling for their growth 
is critical for the optimal selection of patients for therapy.
One molecule that has been shown to be involved in 
resistance to EGFR inhibitors in different tumor types 
is MET, the receptor tyrosine-kinase for hepatocyte 
growth factor (HGF) [19]. MET can activate many of the 
same downstream signaling pathways as EGFR, such as 
ERK1/2 and PI3K/AKT; additionally, it promotes tumor 
growth by affecting proliferation, anti-apoptosis, inva-
sion, and angiogenesis in several tumor types [20]. In 
HNSCC, MET is expressed on epithelial cells and is 
activated by HGF through a paracrine mechanism. HGF 
is synthesized by stromal fibroblasts as an inactive pre-
cursor, and requires activation to generate responses 
via MET stimulation in the target cells [21]. Reports of 
lung, colorectal carcinoma, and glioblastoma have shown 
that MET is activated in the presence of EGFR blockade 
as a compensatory pathway, resulting in a mechanism 
of acquired resistance to EGFR inhibitors [22, 23]. MET 
and HGF are both consistently overexpressed in HNSCC 
[24], and such overexpression correlates with an aggres-
sive disease and poor prognosis [25, 26]. Following sev-
eral reports that established the HGF/MET pathway as 
an important driving force in HNSCC metastasis, and 
after some studies correlated its expression with the clin-
icopathological parameters and the survival of HNSCC 
patients [27], several clinical trials (http://clinicaltri-
als.gov) were conducted with HGF antagonists (rilotu-
mumab, ficlatuzumab) and MET inhibitors (foretinib, 
crizotinib) in order to determine whether the inhibition 
of the HGF/MET pathway may be of therapeutic benefit 
in HNSCC patients [28].
In addition to HGF and MET overexpression, this path-
way can also be activated through genetic alterations 
such as MET-activating mutations that, although rare 
in all tumor types, are certainly contributing to carcino-
genesis. Two somatic activating MET mutations have 
been identified in HNSCC (Y1248C, and Y1253D), which 
increase the kinase activity of MET and subsequently lead 
to tumor proliferation and metastasis [29]. Additionally, 
evidence suggests that EBV and HPV infections are risk 
factors for the development of HNSCC. Viral infection 
has a prognostic impact on HNSCC, and of these, HPV-
positive cancers have a more favorable prognosis [30], 
whereas the HPV-negative group, overwhelmingly made 
up of tobacco-related cancers, is the highest-risk group 
and has the worse prognosis [31]. However, few studies 
have investigated the association of the HGF/MET path-
way expression/activation with HPV status [32].
Owing to the above mentioned, MET has been estab-
lished as a marker of biological significance in cancer. We 
have investigated the impact on cetuximab sensitivity of 
HGF and MET overexpression, MET activation, MET 
gene status, and MET mutations in recurrent/metastatic 
HNSCC patients. We show that MET and p-MET overex-
pression are associated with poor outcome in recurrent/
metastatic patients. In addition, we find that phospho-
rylation of MET is an independent prognostic factor 
in these patients. Taken together, our results support 
the idea that HGF/MET pathway might act as a resist-
ance mechanism against EGFR inhibition in advanced 
HNSCC [33]. Consequently, a dual blocking strategy with 
anti-HGF/MET and -EGFR therapy may be an effective 
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approach that would eventually benefit HNSCC patients 
who are resistant to other therapies.
Methods
Patients and tumor samples
A single-institution retrospective analysis including 57 
consecutive HNSCC patients from Fundacion Jimenez 
Diaz Biobank (Madrid) was carried out, including clinical 
follow-up. The study examined 33 recurrent/metastatic 
patient samples (test group) along with 24 non-recur-
rent/metastatic patient samples (control group). Recur-
rent/metastatic patients were subsequently treated with 
cetuximab. Tissue microarrays were constructed with 
biopsy 1.0  mm cores from formalin-fixed and paraffin-
embedded (FFPE) tumor biopsies obtained before treat-
ment, using a semiautomatic tissue arrayer (Beecher 
Instruments, USA); they contained three cores per sam-
ple from representative areas of tumor.
Protein abundance determination 
by immunohistochemistry (IHC)
For each case, FFPE samples were assayed for EGFR, 
HGF, total and phosphorylated MET using the follow-
ing antibodies: EGFR (D38B1) rabbit mAb (Cell Signal-
ing, USA), HGF (4C12.1) mouse mAb (Millipore, USA), 
MET (SP44) mouse mAb (Ventana Medical Systems, 
USA), and p-MET Y1234/1235 (3D7) rabbit mAb (Cell 
Signaling). Immunostaining was performed as described 
previously [34]. As a positive control, sections of NSCLC 
tumors with known marker expression were stained. Sec-
tions from the same specimens incubated with normal 
mouse and rabbit IgG2 instead of primary antibodies 
were used as negative controls. Antigen preservation in 
tissues was confirmed by assaying sections from the same 
tissue array for expression of phospho-tyrosines, using an 
anti-phosphotyrosine mAb (4G10, Millipore).
Stainings were evaluated by two pathologists (F.R. and 
E.G.). HGF was evaluated in tumoral stroma; EGFR, 
MET and p-MET were quantified in the membrane of 
tumor cells. In addition, a semiquantitative histoscore 
(Hscore) was calculated by estimation of the percentage 
of tumor cells positively stained with low, medium, or 
high staining intensity after applying a weighting factor 
to each estimate. The formula used was Hscore =  (low 
%) × 1 +  (medium %) × 2 +  (high %) × 3, and results 
ranged from 0 to 300.
HPV in situ hybridization
The Ventana Benchmark XT platform for ISH (Ven-
tana) was used for HPV detection. Briefly, sections were 
assayed for HPV DNA by in  situ hybridization with 
INFORM HPV-III Family-16 Probe(B) cocktail for 12 
high-risk genotypes, and visualized using the ISH iVIEW 
PlusDetection Kit (Ventana). The high-risk HPV ISH 
test was scored as positive if there was any blue reaction 
product that co-localized with the nuclei of malignant 
cells.
The digene HC2 High-Risk HPV DNA Test (Qiagen, 
Germany) was used as a confirmatory assay for HPV 
detection. The test allows for the qualitative detection of 
13 high-risk genotypes. Assays were performed following 
the manufacturer’s instructions and the chemilumines-
cent signals were measured in a DML instrument. Sam-
ples with processed values ≥1.0 are considered positives.
Gene expression analysis by quantitative PCR
The levels of EGFR and HGF gene expression were 
determined using a quantitative RT-RealTime PCR 
assay on 5  ×  10  μm sections of the FFPE biopsies, 
using an ATP5E gene as a housekeeping reference. 
Primers were designed to detect all variants accord-
ing to the mRNA sequences NM_005228.3 for EGFR; 
NM_000601.4 (variant 1), NM_001010931.1 (variant 2), 
NM_001010932.1 (variant 3), NM_001010933.1 (vari-
ant 4), and NM_001010934.1 (variant 5) for HGF; and 
NM_006886.2, and NM_001001977.1 for ATP5E. qPCRs 
were conducted in a LightCycler480 II system (Roche 
Applied Science, Switzerland) using the following sets of 
primers: EGFR, 5′-GCTTGGATCCAAAGGTCATC and 
5′-CAAGTGGATGGCATTGGAATC; HGF, 5′-GTGAC 
CAAACTCCTGCCAG and 5′-CTTCTTTTCCTTTG 
TCCCTCTG; ATP5E, 5′-CCGGCGTCTTGGCGATTC 
and 5′-GATCTGGGAGTATCGGATG.
Relative EGFR and HGF expression ratios were cal-
culated using the Pfaffl method [35] relative to the cali-
brator sample (MVP Human Breast Total RNA, Agilent 
Technologies, USA). The efficiencies of every primer pair 
were estimated by a standard curve (Additional file  1: 
Figure S1A).
Dual‑color in situ hybridization
The MET gene copy number was assessed by silver-
enhanced in  situ hybridization (SISH) on tissue micro-
array sections. Automated dc-SISH INFORM probes 
(Ventana) were performed on the Ventana Benchmark 
XT staining platform by labeling the 7q31 region that 
contains the MET gene and the centromeric alpha-sat-
ellite region, specific for chromosome 7, according to 
the manufacturer’s protocol. The following data were 
recorded for each sample: mean MET gene and mean 
CEP7 copy number per cell and MET/CEP7 ratio in 50 
nuclei for each core. Evaluable results—at least one core 
with valid MET and CEP7 counts—were obtained for all 
cases. The status of the EGFR gene was assessed by fluo-
rescence in situ hybridization (FISH) using the LSI EGFR 
(7p12) FISH probe (Ventana), labeling the centromeric 
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alpha-satellite region specific for chromosome 7 (spec-
trum green), and the EGFR gene region (spectrum 
orange), as recommended. The assessment of gene copy 
number was performed independently and blinded from 
IHC by two investigators (F.R. and S.Z.).
Mutation analysis
Pyrosequencing was used to evaluate the status of 
selected Y1248C and Y1253D MET gene mutations on 
4 × 10 μm sections from each tumor. Since both muta-
tions localize very closely in exon 19, we used the same 
set of 3 primers. The sequences were as follows: MET.
exon19, 5′-TGTCCTTTCTGTAGGCTGGATG and 
5′-[Btn]AATACATTACCACATCTGACTTG; sequenc-
ing primer, 5′-GCTGATTTTGGTCTTGCC. Fifty ng of 
DNA were PCR amplified, modified, and finally pyrose-
quenced on a PyroMark ID system (Qiagen) following 
the manufacturer’s instructions. Cut-off value vas set to 
8 % nucleotide mutation.
Statistical analysis
Statistical analysis was carried out with IBM SPSS Sta-
tistics version 21.0. Overexpression criteria were defined 
by receiver operating characteristic (ROC) curve for each 
protein. ROC analysis was used to determine the opti-
mal cut-off value based on the progression endpoint for 
each protein, in agreement with the methodology used 
in prognostic studies [36]. Amplification was defined by 
≥3 copies in at least 2 of the 3 tumor areas studied. To 
analyze correlations between HGF, MET, and p-MET 
protein expression and clinical-pathological variables, 
we used the χ2 test (Fisher’s exact test) or Mann–Whit-
ney test. Overall survival (OS) was defined as the time 
elapsed from the date of initial diagnosis to the date of 
death from any cause or the date of last follow-up. Pro-
gression-free survival (PFS) was defined as the time from 
treatment to either progressive disease or death from any 
cause, censored at last contact [11]. Survivals were ana-
lyzed by the Kaplan–Meier method (median follow-up 
75 months) and curves were compared using the log-rank 
test. Multivariate analysis, including continuous quanti-
tative and qualitative clinical-pathologic parameters, was 
carried out using the Cox proportional hazards model. 
All statistical tests were conducted at the two-sided 0.05 
level of significance. This work was performed in accord-
ance with the Reporting Recommendations for Tumor 
Marker Prognostic Studies (REMARK) guidelines [37].
Results
MET expression and activation in recurrent/metastatic 
HNSCC
Clinical-pathological features for both test and control 
groups of patients are summarized in Table 1. HPV status 
was negative for the majority of the samples (1 positive 
case by both determination methods). We defined the 
optimal overexpression threshold that could be used as 
prognostic marker for MET, p-MET, and HGF. The area 
under the ROC curve (C-statistic) was calculated for every 
case based on the progression endpoint for each protein 
(Fig. 1). MET achieved an area under the curve (AUC) of 
0.837, whereas p-MET and HGF had lower and compara-
ble diagnostic performance (AUC ~0.630 in both cases). 
The optimal cut-off points for MET, p-MET, and HGF 
were calculated at Hscores of 120, 10, and 100, respectively.
EGFR elevated expression was confirmed in all the 
cases, both at the gene (Additional file  1: Figure S1B) 
and protein level (Fig. 2a). MET expression, on the other 
hand, revealed a heterogeneous pattern in the tumors 
studied (Fig.  2a). Expression ranged from homogene-
ous intense staining to complete absence of signal (range 
10–300; median 120). Differences in intensity of MET 
expression were occasionally detected in the same tumor. 
In total, overexpression of MET was detected in 33 (58 %) 
of all patients: in 22 (67 %) of the test samples and in 11 
(46 %) of the control samples (Table 2; Fig. 2c). The detec-
tion of phosphorylated Y1234/1235 MET also showed a 
grading along the series (Fig.  2a) (range 0–180; median 
80). p-MET overexpression was detected in 17 (30  %) 
patients in the whole series, in 12 (36 %) of the test, and 
in 5 (21 %) of the control cases (Table 2).
MET gene amplification was next assessed for the 57 
cases (Fig. 2b). Twenty-two cases (39 %) exhibited ampli-
fication of the region corresponding to the MET locus, 
15 of them corresponding to test samples (Table  2). 
Although the fraction of overexpressing/amplified cases 
was quantitatively higher in the test group, the differ-
ences for these markers between the two groups were 
not found to be statistically significant. In consequence, 
we calculated the correlations between markers for the 
complete series. Significant correlations were found 
between MET gene amplification and overexpression 
(Table 3) (P = 0.004). In our series, all the cases display-
ing gene amplification except one also showed high levels 
of receptor expression, confirming the straightforward 
link between genomic dose and protein synthesis. All the 
test cases that showed MET amplification were also over-
expressing the protein (100 %). In the case of the control 
samples, 6 out of the 7 (86  %) patients with amplifica-
tion showed high levels of MET expression. Additionally, 
other significant associations were found between recep-
tor activation with gene amplification (P  =  0.047) and 
receptor expression (P = 0.013).
HGF gene is moderately overexpressed in HNSCC
Elevated levels of ligand HGF are coupled with activa-
tion of the MET receptor. The expression levels of the 
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HGF gene in the samples were verified by qPCR (Addi-
tional file  1: Figure S1B). The number of positive cases 
was 33 (58  %), 18 (55  %) of whom from the test group 
and 15 (62 %) from the control group. There was a rea-
sonable agreement with the HGF protein determination 
by IHC. Additionally, a similar pattern of sample het-
erogeneity was visualized in the immunohistochemical 
expression of the HGF protein. The signal for HGF was 
mainly visualized in the surrounding stroma but not in 
the tumoral cells, as opposed to the images of MET and 
Table 1 Clinical characteristics of test and control groups of patients
NA not applicable, ND no data available
a Cycles, range (median)
b Months, range (median)
Test group Control group P value
n % n %
Age [mean (range)] 61 (38–80) 64 (41–80) 1
Sex 0.059
 Male 31 96.2 18 75.0
 Female 2 3.8 6 25.0
Performance status 0.444
 0 1 3.0 0 0
 1 32 97.0 19 79.2
 ND 5 20.8
Smoking history 0.912
 Current smoker 11 33.3 9 37.5
 Former smoker 21 63.6 14 58.3
 Never smoker 1 3.0 1 4.2
Primary site 0.952
 Oral cavity 7 21.2 6 25.0
 Oropharynx 7 21.2 4 16.7
 Hypopharynx 6 18.2 4 16.7
 Larynx 12 36.4 10 41.7
 ND 1 3.0
Failure sites
 Locoregional 28 87.5 NA
 Distance 19 59.4 NA
 Both 10 31.3 NA
Therapeutic regimen Lengtha Follow‑upb Lengtha Follow‑upb
 Cetuximab 15 45.5 4–64 (12) 15–76 (30) NA
 Cetuximab/platinum/5FU 13 39.4 4–56 (22) 6–74 (33) NA
 Cetuximab/taxane 5 15.1 20–32 (24) 24–26 (25) NA
 Chemotherapy (CDDP) NA 5 20.8 3 (3) 9–121 (40)
 No chemotherapy 13 54.2
 ND 6 25
Skin toxicity
 Rash grade 1 7 21.2 NA
 Rash grade 2 11 33.3 NA
 Rash grade 3 5 15.2 NA
 ND 10 30.3
Hypomagnesemia
 Yes 6 18.2
 No 15 45.5
 ND 12 36.4 24
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p-MET (Fig.  2a). With respect to the potential role of 
HGF gene overexpression in MET activation, 8/17 sam-
ples (47 %) that had shown p-MET overexpression did in 
fact hold elevated mRNA levels of its ligand. Importantly, 
HGF overexpression was associated with MET phospho-
rylation (P = 0.001), suggesting a paracrine activation of 
the receptor (Table 3).
MET mutation analysis
Sequencing screening was performed for the two most 
frequent Y1248 and Y1253 MET mutations in HNSCC. 
One case (2  %) was deemed positive with 12  % muta-
tion TGT in position Y1248. In addition to the pyrose-
quencing analysis, de novo sequencing was performed 
in the amplified 34-nucleotide length region spanning 
Fig. 1 MET (a), p‑MET (b), and HGF (c) overexpression thresholds in the cohort of HNSCC patients. ROC curves were used to calculate the optimal 
biomarker thresholds based on the progression endpoint for each protein. These scores, in correspondence, defined protein overabundance. Full 
lines represent the ROC curves; in dot lines, the diagonal reference lines
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the Y1248 and Y1253 area in the MET locus, in order to 
check for the presence of hotspots surrounding the 2 tar-
geted codons 1248 and 1253.
Prognostic role of the MET pathway in cetuximab‑treated 
HNSCC patients
To provide data regarding the prognostic impact of MET 
expression and activation in human HNSCC under a 
cetuximab-based treatment, we performed a survival 
analysis of our series of patients, stratifying the status of 
the markers. Kaplan–Meier curves for MET and p-MET 
in PFS and OS were calculated. Both MET and p-MET 
overexpression revealed a poor outcome in HNSCC 
patients from the test group (Fig.  3). Log-rank testing 
showed a significantly worse outcome in MET-overex-
pressing patients for PFS (P = 0.002) and OS (P = 0.045). 
p-MET expression was also significantly associated with 
a poor clinical outcome for OS (P < 0.001). Patients with 
p-MET overexpression had worse prognosis (median 
PFS 15  months; median OS 18  months) compared 
Fig. 2 HGF/MET pathway expression and activation in recurrent/metastatic HNSCC. a Representative pictures showing a range of EGFR, MET, 
p‑MET, and HGF expression levels observed by IHC in human HNSCC. b MET identification in FFPE tissue samples by SISH. Left panel detail of a 
MET‑amplified case (clusters of black dots are seen in the nuclei of tumoral cells, representing several copies of the MET locus; as opposed to just 
two red dots per cell, corresponding to the centromeric region on chromosome 7). Right panel non‑amplified sample. c Protein expression levels 
and gene amplification in the complete series. Case numbers are ordered from test (#1–33) to controls (#34–57), and a dashed line has been drawn 
in between the two groups. The color intensity of the boxes is indicative of abundance level in each column, either protein level by IHC (EGRF, MET, 
p‑MET, HGF) or gene amplification level by SISH (MET gene). Expression levels are indicated in a color gradient, from white (minimum) to red (maxi‑
mum), with missing data in gray
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with p-MET negative/low expression cases (median 
PFS 37  months; median OS 48  months). Moreover, 
p-MET overexpression also correlated with worse PFS 
(P =  0.014). Multivariate Cox analysis in the test group 
(Table  4) confirmed the independent prognostic signifi-
cance of p-MET for PFS (HR 6.5; 95 % CI 1.5–8.9) and for 
OS (HR 8.2; 95 % CI 0.2–14.6). No significant association 
of HGF overexpression with clinic-pathological param-
eters was detected. Histological staging did not show any 
significant impact in the survival of the patients.
Discussion
We have retrospectively addressed the correlation of 
HGF/MET pathway overexpression and activation 
with cetuximab response in samples from patients that 
later developed recurrent/metastatic HNSCC, and we 
have concluded that it correlated with worse outcome 
in patients treated with a cetuximab-based regimen. 
The point that samples were collected prior to treat-
ment suggests that it may act as a primary resistance 
mechanism for EGFR inhibitors. Previous studies have 
already reported that primary resistance can decrease the 
response rate to EGFR-targeted therapies [15]. An addi-
tional activation of the HGF/MET pathway—that may 
function as a compensatory route—has been reported in 
some other tumors [19, 38], but the first description of 
MET overexpression in HNSCC patients [39] was pub-
lished only recently. In agreement with previous studies, 
our work demonstrates that MET was expressed in 58 % 
of HNSCC patients in our total series, and that p-MET 
was expressed to a lesser extent, in just 30 % of cases, with 
no significant differences between the test and control 
groups. Our series also shows a tight correlation between 
MET gene amplification and MET overexpression in 
HNSCC patients (Fig. 2c). These findings reveal a direct 
link between gene amplification, gene high expression, 
and protein overabundance. Given that several studies 
indicate that MET activation is responsible for approxi-
mately 20 % of resistance to EGFR inhibitors [29, 40], our 
results suggest a condition of potential primary resistance.
Biomarker levels were determined in samples collected 
at the time of initial diagnosis but not at the time of 
recurrence/metastasis diagnosis, in order to avoid levels 
alterations due to additional chemotherapy treatments. 
Although expression levels might fluctuate from diagno-
sis to recurrence/metastasis, biomarkers at the time of 
diagnosis are characteristic of every individual, and their 
profiles possess prognostic value to evaluate the progres-
sion of the disease.
Resistance to EGFR-inhibition therapies is a growing 
concern in HNSCC clinical practice, due to both primary 
resistance and to the development of acquired resistance 
by many patients that only respond transiently to therapy 
with EGFR-targeted drugs [41]. The study of resistance to 
cetuximab therapy in HNSCC closely echoes the strate-
gies used to uncover the mechanisms of resistance to 
tyrosine kinase inhibitors (gefitinib, erlotinib) in other 
tumor types [17, 42]. Setting aside the mutations on the 
EGFR kinase domain (cetuximab targets the extracellular 
Table 2 EGFR, MET, p-MET, HGF protein expression levels 
and MET gene amplification in the complete series
Different ranges included those cases with low (0–33 %), medium (34–66 %), or 
high (67–100 %) IHC expression levels determined as a percentage of the Hscore
Expression levels test Group Control group P value
n % n %
EGFR 0.053
 Low 0 0.0 2 8.3
 Medium 2 6.1 3 12.5
 High 25 75.7 19 79.2
 ND 6 18.2
MET 0.066
 Low 8 24.2 16 66.7
 Medium 16 48.5 5 20.8
 High 9 27.3 3 12.5
p‑MET 0.060
 Low 27 81.8 20 83.3
 Medium 4 12.1 4 16.7
 High 2 6.1 0 0.0
MET gene 0.092
 Yes 17 51.5 7 29.2
 No 16 48.5 17 70.8
HGF 0.369
 Low 9 27.3 11 45.8
 Medium 17 51.5 10 41.7
 High 7 21.2 3 12.5
Table 3 Correlations between biomarkers expressed as P values (Chi square test)
Expression levels as determined by IHC. Results include all 57 patients
MET overexpression p‑MET overexpression HGF overexpression MET amplification
MET overexpression 0.013 0.517 0.004
p‑MET overexpression 0.013 0.001 0.047
HGF overexpression 0.517 0.001 0.786
MET amplification 0.004 0.047 0.786
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domain of EGFR, and therefore its mechanism of action 
does not affect the tyrosine kinase domain), MET ampli-
fication represents the most obvious focus of research, in 
terms of prevalence. EGFR shares important downstream 
signaling targets with MET, another transmembrane 
tyrosine-kinase receptor, including ERK1/2, PI3K/AKT, 
STAT3, and PLCγ. The HGF/MET signaling pathway can 
be activated by MET genomic amplification [19], by over-
expression of the ligand HGF [38] or the MET receptor 
kinase, or by its activating mutations [29, 43]. In all cases, 
MET activation occurs by phosphorylation of any of sev-
eral residues in the tyrosine-kinase domain. A sustained 
activation of common EGFR and MET downstream tar-
gets leads to malignant growth [44].
In vitro studies of MET and EGFR have shown that a 
single amplified receptor tyrosine-kinase can determine 
growth and survival of different cancer cell lines (lung, 
gastric). It was found that the amplified MET was con-
stitutively activated, suggesting an oncogene addiction 
phenomenon that was required for cell survival [45]. 
Our present results would now demonstrate that this 
in vitro requirement may correlate with in vivo growth in 
patients.
Furthermore, our data suggest that, in case of gene 
amplification, HGF liberation may not be required for 
MET activation. Conversely, it may be necessary for those 
cases with no MET amplification. In fact, HGF overexpres-
sion did not correlate with MET amplification (P = 0.786), 
Fig. 3 Prognostic role of MET and p‑MET in cetuximab‑treated HNSCC patients. a Progression‑free survival (PFS) for MET. b Overall survival (OS) for 
MET. c PFS for p‑MET. d OS for p‑MET. In light gray line, patients with MET overexpression; in black line, patients without MET overexpression
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although it was associated with MET phosphorylation 
(P = 0.001), suggesting a paracrine activation of the recep-
tor (Table 3). It seems that, in these cases, a greater con-
centration of HGF and/or proximal interaction of tumor 
and stromal cells are critical for the activation of the MET 
pathway (although HGF measurements include the stro-
mal pool, and thus they do not necessarily equate with its 
active form). As has been demonstrated in murine models, 
while HGF was secreted by HNSCC tumor-derived fibro-
blasts, but not by HNSCC cells, MET was expressed and 
functional in HNSCC cells [39]. Addition of HGF induced 
MET phosphorylation, leading to the activation of AKT 
and ERK, and tumor proliferation, confirming that HGF 
acts mainly as a paracrine factor in HNSCC cells.
Regarding the third possible mechanism of MET acti-
vation, two somatic constitutively active MET mutations 
have been identified in lymph node metastases of HNSCC 
(Y1248C and Y1253D) [46]. Only one Y1248C muta-
tion (2 %) was found in the MET locus (none in Y1253), 
probably due to the small probability of finding low-
prevalence mutations in our small series. Although these 
mutations are barely detectable in primary tumors from 
patients, it has been shown that cells carrying the muta-
tions are selected during the metastatic spread [46]. This 
is in agreement with our hypothesis that MET pathway 
activity mechanisms preexist in the HNSCC population, 
and subsequent treatment with anti-EGFR therapy may 
expose processes of resistance. Intriguingly, we found four 
hotspots near these two positions, wherein the propor-
tions of non-canonical nucleotide incorporation were sig-
nificantly elevated. This point merits further research, as it 
might indicate that these areas in the MET gene tend to 
accumulate mutations in the tumoral cells, and it might be 
related to the mechanisms and consequences of the previ-
ously described Y1248 and Y1253 mutations in HNSCC.
From a clinical perspective, the most relevant finding 
of this study was the prognostic role of MET and p-MET 
expression in HNSCC. In the literature debate surrounds 
the possible prognostic role of total MET in human can-
cer, with many studies suggesting a negative prognostic 
role [20, 47], while others indicate the contrary [40, 48], 
and some studies even discern no relationship at all. With 
respect to MET phosphorylation, our data suggest that it 
may an independent prognostic factor in these patients. 
Since this is a surrogate marker of receptor activation, 
our finding is consistent with an adverse role of activated 
MET receptor in HNSCC, supporting the findings of pre-
vious reports that correlate increased MET activation 
with resistance to cetuximab in both HNSCC cell lines 
[19] and patient-derived xenografts [49]. In other tumor 
Table 4 Multivariate cox regression models for progression-free survival (PFS) and overall survival (OS) in the 33 cetuxi-
mab-treated patients
Firstly, univariate analysis was performed for the descriptive variables, and then we executed a multivariate analysis on those significant variables. Since MET, p‑MET 
and HGF expression are associated with each other, we performed separate analysis for each marker
HR hazard ratio, CI confidence interval, ND not enough data available
PFS OS
HR 95 % CI P value HR 95 % CI P value
Smoking history 0.268 0.786
 Ex‑smoker 1.0 ND
 Smoker 2.2 0.2–20.9 ND
 Non‑smoker 0.4 0.2–1.9 ND
Primary site 0.184 0.389
 Larynx 1.0 1.0
 Oropharynx 0.3 0.5–2.2 0.3 0.1–4.6
 Oral cavity 2.8 0.4–10.2 2.1 0.4–6.3
 Hypopharynx 2.1 0.3–8.3 2.6 0.1–10.2
Histological grade 0.090 0.719
 Well‑differentiated 1.0 1.0
 Moderately differentiated 4.6 2.5–7.6 0.9 0.1–3.2
 Poorly differentiated 3.2 2.3–8.5 1.9 0.1–4.1
Alcohol 2.1 0.7–10.3 0.381 6.2 0.1–34.2 0.413
MET overexpression 7.6 4.6–10.4 0.060 4.9 0.1–8.5 0.070
p‑MET overexpression 6.5 1.5–8.9 0.002 8.2 0.2–14.6 0.022
HGF overexpression 6.6 1.2–8.4 0.059 2.2 0.2–2.1 0.110
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types similar conclusions about the role of activated MET 
have been drawn [34].
Since the first reports of EGFR-targeted therapy in 
HNSCC, it has been known that EGFR expression is 
needed for cetuximab response, although EGFR expres-
sion does not predict response. Our data suggest that 
combined treatments of a MET inhibitor and cetuxi-
mab may be cumulative, and therefore dual blocking of 
EGFR and HGF/MET pathways could be a reasonable 
therapeutic option for clinical practice. Among the vari-
ous options for inhibiting MET, most efforts concern to 
the use of small molecule inhibitors of MET, or antibody 
inhibitors of MET or its ligand, HGF [50].
Conclusions
Due to the limited number of patients in our study and 
the fact that our analysis did not include a validation 
cohort, we must assume the conclusions as a preliminary 
indication of the role of the HGF/MET pathway regard-
ing cetuximab resistance in HNSCC. We have confirmed 
that the pathway is overexpressed and overactivated in 
HNSCC patients. This activation of MET is constitutive 
in those patients with MET gene amplification, while 
HGF overexpression is required for MET activation in 
non-amplified cases. In recurrent/metastatic HNSCC 
patients, MET and p-MET overexpression are associ-
ated with poor outcome, and phosphorylation of MET 
is considered an independent prognostic factor in these 
patients. Finally, and in accordance with previous sugges-
tions in different cancer types, we propose that the HGF/
MET pathway might act as a primary resistance mecha-
nism for EGFR inhibitors. The absence of a correlation 
between HGF/MET pathway activity and outcome in 
the control group is a significant finding that reinforces 
this hypothesis. Consequently, we would contemplate a 
dual blocking of both routes, in a combination therapy 
of EGFR and HGF/MET tyrosine-kinase inhibitors, for 
those patients with recurrent or metastatic HNSCC.
Authors’ contributions
Conceived and designed the experiments: JMG, JGF, FR. Performed the 
experiments: SZ, CC, IC. Analyzed the data: JMG, EG, FR. Contributed reagents/
Additional file
Additional file 1: Figure S1. Representative qRT‑PCR analysis for EGFR 
and HGF mRNA copy levels. A. Standard curves for target EGFR, HGF and 
reference probe ATP5E, as determined by 5 or 8 triplicate points over a 
range from 0.05 to 10 ng. The efficiencies (E) were calculated from the 
slope of the standard curves according to the equation: E = (10[‑1/slope]‑1), 
by using 5 or 8 dilution points. The efficiencies were determined as fol‑
lows: EEGFR= 1.974; EHGF= 2.091; EATP5E= 1.902. RFU, relative fluorescence 
units. B. qPCR amplification curves of EGFR, HGF and ATP5E probes, in 
triplicate, for a representative sample, showing the distance with the 
calibrator sample.
materials/analysis tools: VC, CC. Wrote the paper: JMG, FR. All authors read and 
approved the final manuscript.
Author details
1 Molecular Pathology Laboratory, IIS‑Fundacion Jimenez Diaz, UAM, Avda. 
Reyes Catolicos 2, 28040 Madrid, Spain. 2 Oncology Department, Fundacion 
Jimenez Diaz, Madrid, Spain. 3 Pathology Department, IIS‑Fundacion Jimenez 
Diaz, UAM, Avda. Reyes Catolicos 2, 28040 Madrid, Spain. 4 Translational Oncol‑
ogy Department, IIS‑Fundacion Jimenez Diaz, UAM, Madrid, Spain. 
Acknowledgements
We thank Oliver Shaw for linguistic correction of the manuscript. The present 
work was supported by grants from the Spanish Ministerio de Economia y 
Competitividad (MINECO) (AES Program, grant PI12/01552); the Ministerio de 
Sanidad (Cancer Network); the Comunidad de Madrid (S2010/BMD‑2344). 
The Fundacion Jimenez Diaz Biobank is funded by a grant from the MINECO 
(Instituto de Salud Carlos III, RETICS Red de Biobancos, with FEDER funds, 
RD09/0076/00101). S.Z. and C.C. are supported by grants from the same 
Biobanks initiative.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 13 May 2015   Accepted: 10 August 2015
References
 1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer 
J Clin 63(1):11–30. doi:10.3322/caac.21166
 2. Licciardello JT, Spitz MR, Hong WK (1989) Multiple primary cancer in 
patients with cancer of the head and neck: second cancer of the head 
and neck, esophagus, and lung. Int J Radiat Oncol Biol Phys 17:467–476
 3. Gold KA, Lee HY, Kim ES (2009) Targeted therapies in squamous cell 
carcinoma of the head and neck. Cancer 115:922–935
 4. Vermorken JB, Specenier P (2010) Optimal treatment for recurrent/meta‑
static head and neck cancer. Ann Oncol 21(Suppl 7):vii252–vii261
 5. Kundu SK, Nestor M (2012) Targeted therapy in head and neck cancer. 
Tumour Biol 33:707–721
 6. Kalyankrishna S, Grandis JR (2006) Epidermal growth factor receptor biol‑
ogy in head and neck cancer. J Clin Oncol 24:2666–2672
 7. Chung CH, Ely K, McGavran L, Varella‑Garcia M, Parker J, Parker N, Jarrett C, 
Carter J, Murphy BA, Netterville J et al (2006) Increased epidermal growth 
factor receptor gene copy number is associated with poor prognosis in 
head and neck squamous cell carcinomas. J Clin Oncol 24:4170–4176
 8. Loeffler‑Ragg J, Schwentner I, Sprinzl GM, Zwierzina H (2008) EGFR inhibi‑
tion as a therapy for head and neck squamous cell carcinoma. Expert 
Opin Investig Drugs 17:1517–1531
 9. Aboud‑Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M (1988) 
Efficacy of antibodies to epidermal growth factor receptor against KB 
carcinoma in vitro and in nude mice. J Natl Cancer Inst 80:1605–1611
 10. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan 
J, Zabolotnyy D, Kienzer HR, Cupissol D et al (2008) Platinum‑based 
chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 
359:1116–1127
 11. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA (2005) East‑
ern Cooperative Oncology G: phase III randomized trial of cisplatin plus 
placebo compared with cisplatin plus cetuximab in metastatic/recurrent 
head and neck cancer: an Eastern Cooperative Oncology Group study. J 
Clin Oncol 23:8646–8654
 12. Gillison ML, Glisson BS, O’Leary E, Murphy BA, Levine MA, Kies MS, Chan 
D, Forastiere AA (2006) Phase II trial of trastuzumab (T), paclitaxel (P) and 
cisplatin (C) in metastatic (M) or recurrent (R) head and neck squamous 
cell carcinoma (HNSCC): response by tumor EGFR and HER2/neu status. J 
Clin Oncol 24:282S
Page 12 of 13Madoz‑Gúrpide et al. J Transl Med  (2015) 13:282 
 13. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, 
Baselga J, Spencer SA, Zhu J et al (2010) Radiotherapy plus cetuximab for 
locoregionally advanced head and neck cancer: 5‑year survival data from 
a phase 3 randomised trial, and relation between cetuximab‑induced 
rash and survival. Lancet Oncol 11:21–28
 14. Baselga J, Averbuch SD (2000) ZD1839 (‘Iressa’) as an anticancer agent. 
Drugs 60(Suppl 1):33–40 discussion 41–32
 15. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan 
BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al (2004) Activat‑
ing mutations in the epidermal growth factor receptor underlying 
responsiveness of non‑small‑cell lung cancer to gefitinib. N Engl J Med 
350:2129–2139
 16. Wheeler DL, Dunn EF, Harari PM (2010) Understanding resistance to EGFR 
inhibitors‑impact on future treatment strategies. Nat Rev Clin Oncol 
7:493–507
 17. Sharafinski ME, Ferris RL, Ferrone S, Grandis JR (2010) Epidermal growth 
factor receptor targeted therapy of squamous cell carcinoma of the head 
and neck. Head Neck 32:1412–1421
 18. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL (2004) 
Multicenter phase II study of erlotinib, an oral epidermal growth factor 
receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic 
squamous cell cancer of the head and neck. J Clin Oncol 22:77–85
 19. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Linde‑
man N, Gale CM, Zhao X, Christensen J et al (2007) MET amplification 
leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. 
Science 316:1039–1043
 20. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, 
metastasis, motility and more. Nat Rev Mol Cell Biol 4:915–925
 21. Hartmann G, Naldini L, Weidner KM, Sachs M, Vigna E, Comoglio PM, 
Birchmeier W (1992) A functional domain in the heavy chain of scat‑
ter factor/hepatocyte growth factor binds the c‑Met receptor and 
induces cell dissociation but not mitogenesis. Proc Natl Acad Sci USA 
89:11574–11578
 22. Agarwal S, Zerillo C, Kolmakova J, Christensen JG, Harris LN, Rimm DL, 
Digiovanna MP, Stern DF (2009) Association of constitutively activated 
hepatocyte growth factor receptor (Met) with resistance to a dual 
EGFR/Her2 inhibitor in non‑small‑cell lung cancer cells. Br J Cancer 
100:941–949
 23. Jun HJ, Acquaviva J, Chi D, Lessard J, Zhu H, Woolfenden S, Bronson RT, 
Pfannl R, White F, Housman DE et al (2012) Acquired MET expression 
confers resistance to EGFR inhibition in a mouse model of glioblastoma 
multiforme. Oncogene 31:3039–3050
 24. Galeazzi E, Olivero M, Gervasio FC, De Stefani A, Valente G, Comoglio PM, 
Di Renzo MF, Cortesina G (1997) Detection of MET oncogene/hepato‑
cyte growth factor receptor in lymph node metastases from head and 
neck squamous cell carcinomas. Eur Arch Otorhinolaryngol 254(Suppl 
1):S138–S143
 25. Uchida D, Kawamata H, Omotehara F, Nakashiro K, Kimura‑Yanagawa 
T, Hino S, Begum NM, Hoque MO, Yoshida H, Sato M, Fujimori T (2001) 
Role of HGF/c‑met system in invasion and metastasis of oral squamous 
cell carcinoma cells in vitro and its clinical significance. Int J Cancer 
93:489–496
 26. Lo Muzio L, Leonardi R, Mignogna MD, Pannone G, Rubini C, Pieramici T, 
Trevisiol L, Ferrari F, Serpico R, Testa N et al (2004) Scatter factor receptor 
(c‑Met) as possible prognostic factor in patients with oral squamous cell 
carcinoma. Anticancer Res 24:1063–1069
 27. Freudlsperger C, Alexander D, Reinert S, Hoffmann J (2010) Prognostic 
value of c‑Met expression in oral squamous cell carcinoma. Exp Ther Med 
1:69–72
 28. Seiwert TY, Swann S, Kurz H, Bonate P, McCallum S, Sarantopoulos JA 
(2009) Phase II study of the efficacy and safety of foretinib, a novel recep‑
tor tyrosine kinase inhibitor, given on an intermittent 5 days on 9 days 
off (5/9) schedule in patients with recurrent or metastatic squamous cell 
cancer of the head and neck (SCCHN). Mol Cancer Ther 8:B6
 29. Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich 
S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T et al (2008) 
Expression and mutational analysis of MET in human solid cancers. Genes 
Chromosom Cancer 47:1025–1037
 30. Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, 
Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A (2006) Molecular classification 
identifies a subset of human papillomavirus—associated oropharyngeal 
cancers with favorable prognosis. J Clin Oncol 24:736–747
 31. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, Wolf GT, Urba 
SG, Chepeha DB, Teknos TN et al (2008) EGFR, p16, HPV Titer, Bcl‑xL and 
p53, sex, and smoking as indicators of response to therapy and survival in 
oropharyngeal cancer. J Clin Oncol 26:3128–3137
 32. Kwon MJ, Kim DH, Park HR, Shin HS, Kwon JH, Lee DJ, Kim JH, Cho SJ, 
Nam ES (2014) Frequent hepatocyte growth factor overexpression and 
low frequency of c‑Met gene amplification in human papillomavirus‑
negative tonsillar squamous cell carcinoma and their prognostic signifi‑
cances. Hum Pathol 45:1327–1338
 33. Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM (2011) 
Dual blockade of EGFR and c‑Met abrogates redundant signaling 
and proliferation in head and neck carcinoma cells. Clin Cancer Res 
17:4425–4438
 34. Arriola E, Canadas I, Arumi‑Uria M, Domine M, Lopez‑Vilarino JA, Arpi O, 
Salido M, Menendez S, Grande E, Hirsch FR et al (2011) MET phosphoryla‑
tion predicts poor outcome in small cell lung carcinoma and its inhibi‑
tion blocks HGF‑induced effects in MET mutant cell lines. Br J Cancer 
105:814–823
 35. Pfaffl MW (2001) A new mathematical model for relative quantification in 
real‑time RT‑PCR. Nucleic Acids Res 29:e45
 36. Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga 
A, Allevi G, Milani M, Aguggini S et al (2009) Phosphorylated ERalpha, 
HIF‑1alpha, and MAPK signaling as predictors of primary endocrine treat‑
ment response and resistance in patients with breast cancer. J Clin Oncol 
27:227–234
 37. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) 
Statistics Subcommittee of the NCIEWGoCD: Reporting recommenda‑
tions for tumor marker prognostic studies. J Clin Oncol 23:9067–9072
 38. Liska D, Chen CT, Bachleitner‑Hofmann T, Christensen JG, Weiser MR 
(2011) HGF rescues colorectal cancer cells from EGFR inhibition via MET 
activation. Clin Cancer Res 17:472–482
 39. Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish 
CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM et al (2009) HGF and 
c‑Met participate in paracrine tumorigenic pathways in head and neck 
squamous cell cancer. Clin Cancer Res 15:3740–3750
 40. Cappuzzo F, Janne PA, Skokan M, Finocchiaro G, Rossi E, Ligorio C, Zucali 
PA, Terracciano L, Toschi L, Roncalli M et al (2009) MET increased gene 
copy number and primary resistance to gefitinib therapy in non‑small‑
cell lung cancer patients. Ann Oncol 20:298–304
 41. Mehra R, Serebriiskii IG, Dunbrack RL Jr, Robinson MK, Burtness B, Golemis 
EA (2011) Protein‑intrinsic and signaling network‑based sources of 
resistance to EGFR‑ and ErbB family‑targeted therapies in head and neck 
cancer. Drug Resist Updates 14:260–279
 42. Cohen RB (2014) Current challenges and clinical investigations of epi‑
dermal growth factor receptor (EGFR)‑ and ErbB family‑targeted agents 
in the treatment of head and neck squamous cell carcinoma (HNSCC). 
Cancer Treat Rev 40:567–577
 43. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali 
M, Yala S, Kanteti R, Cohen EE, Lingen MW et al (2009) The MET receptor 
tyrosine kinase is a potential novel therapeutic target for head and neck 
squamous cell carcinoma. Cancer Res 69:3021–3031
 44. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A, 
Nardone J, Innocenti G, Wetzel R et al (2008) Signaling networks assem‑
bled by oncogenic EGFR and c‑Met. Proc Natl Acad Sci USA 105:692–697
 45. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald 
H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC et al (2006) Amplification of 
MET may identify a subset of cancers with extreme sensitivity to the 
selective tyrosine kinase inhibitor PHA‑665752. Proc Natl Acad Sci USA 
103:2316–2321
 46. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, 
Valente G, Giordano S, Cortesina G, Comoglio PM (2000) Somatic muta‑
tions of the MET oncogene are selected during metastatic spread of 
human HNSC carcinomas. Oncogene 19:1547–1555
 47. Kim CH, Koh YW, Han JH, Kim JW, Lee JS, Baek SJ, Hwang HS, Choi EC 
(2010) c‑Met expression as an indicator of survival outcome in patients 
with oral tongue carcinoma. Head Neck 32:1655–1664
 48. Belfiore A, Gangemi P, Costantino A, Russo G, Santonocito GM, Ippolito 
O, Di Renzo MF, Comoglio P, Fiumara A, Vigneri R (1997) Negative/low 
Page 13 of 13Madoz‑Gúrpide et al. J Transl Med  (2015) 13:282 
expression of the Met/hepatocyte growth factor receptor identifies 
papillary thyroid carcinomas with high risk of distant metastases. J Clin 
Endocrinol Metab 82:2322–2328
 49. Krumbach R, Schuler J, Hofmann M, Giesemann T, Fiebig HH, Beckers 
T (2011) Primary resistance to cetuximab in a panel of patient‑derived 
tumour xenograft models: activation of MET as one mechanism for drug 
resistance. Eur J Cancer 47:1231–1243
 50. Comoglio PM, Giordano S, Trusolino L (2008) Drug development of MET 
inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug 
Discov 7:504–516
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
